New Analyses Allow Restart Of Ipsen's Palovarotene Clinical Program

FDA's Partial Clinical Hold For Patients Under 14 Remains

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.